Clinical Trials Browser

Phase 1/2 × toripalimab × Dermatologic × Clear all

Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05723432 2023-04-27

KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma

Phase 1/2 Unknown

84 enrolled

Dermatologic

Melanoma

NCT05539118 2022-09-14

Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma

Phase 1/2 Not yet recruiting

48 enrolled

Dermatologic

Melanoma

Clinical Trials

A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma

Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma